Glycogen synthase kinase 3 (GSK3) was initially described as a key enzyme involved in glycogen metabolism, but is now known to regulate a diverse array of cell functions. The study of the ...

A novel drug combination targeting LSD1 and GSK3 shows promise in treating acute myeloid leukemia by promoting cell differentiation and reducing tumor growth.

A new research perspective was published in Oncotarget, Volume 16, on April 4, 2025, titled "GSK3β activation is a key driver of resistance to Raf inhibition in BRAF mutant melanoma cells.